Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

In fact, more and more teens that meet certain weight and health criteria are going on GLP-1s after the FDA’s approval of ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

After easing diabetes and weight loss journey for many, the popular medications Ozempic and Wegovy have shown ... Researchers ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...

November is Diabetes awareness month. Diabetes (Diabetes mellitus) is a common endocrine disorder in all mammals, dogs and cats included. Diabetes is characterized by a dysfunction of insulin ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

Rybelsus: Novo Nordisk’s name-brand version of oral semaglutide tablets to help improve blood sugar levels (along with diet ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...